Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Phase II Study of GSK2586184 in Systemic Lupus Erythematosus
2012-001645-41Phase 2Terminated
- Sponsor
- GSK
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of solcitinib in systemic lupus erythematosus (SLE), sponsored by GSK. Primary endpoint: Interferon transcriptional signature biomarker expression over time. Started Oct 2012; status: terminated.
02
Drugs
solcitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2012-001645-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001645-41.